GlaxoSmithKline PLC (GSK): Price and Financial Metrics


GlaxoSmithKline PLC (GSK): $45.10

0.22 (+0.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GSK POWR Grades


  • Value is the dimension where GSK ranks best; there it ranks ahead of 94.92% of US stocks.
  • The strongest trend for GSK is in Growth, which has been heading down over the past 163 days.
  • GSK ranks lowest in Momentum; there it ranks in the 12th percentile.

GSK Stock Summary

  • GSK has a market capitalization of $112,379,520,000 -- more than approximately 97.8% of US stocks.
  • GSK's went public 35.56 years ago, making it older than 92.26% of listed US stocks we're tracking.
  • In terms of volatility of its share price, GSK is more volatile than merely 12.37% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Glaxosmithkline Plc are CAT, DE, IBM, SNY, and MMM.
  • Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to www.gsk.com.

GSK Stock Price Chart Interactive Chart >

Price chart for GSK

GSK Price/Volume Stats

Current price $45.10 52-week high $46.85
Prev. close $44.88 52-week low $33.53
Day low $44.84 Volume 5,467,400
Day high $45.47 Avg. volume 4,408,421
50-day MA $43.27 Dividend yield 4.52%
200-day MA $40.51 Market Cap 121.44B

GlaxoSmithKline PLC (GSK) Company Bio


GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company’s wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.


GSK Latest News Stream


Event/Time News Detail
Loading, please wait...

GSK Latest Social Stream


Loading social stream, please wait...

View Full GSK Social Stream

Latest GSK News From Around the Web

Below are the latest news stories about Glaxosmithkline Plc that investors may wish to consider to help them evaluate GSK as an investment opportunity.

Unilever And Glaxo - A Classic Arbitrage Example

A standard arbitrage technique Precisely because this is a standard technique seasoned market players can probably skip most of it. This is more of a guide to those learning about the markets than it is advice to those who already know their stuff. It's also not specifically about Unilever PLC...

Tim Worstall on Seeking Alpha | January 18, 2022

Unilever sees investor backlash over $68B bid for GlaxoSmithKline consumer unit

Unilever Plc (NYSE:UL) is facing investor backlash over its £50B ($68B) offer for GlaxoSmithKline's (NYSE:GSK) consumer business. Unilever shares fell 7% in London, while GSK rose 4.1%. One unidentified top-20 Unilever (UL) told the Financial Times that he's against the deal and would vote against it. GSK and Pfizer Inc. (NYSE:PFE), which...

Seeking Alpha | January 18, 2022

23andMe gets $50M to extend research deal with GSK

23andMe's "absolute amazing journey" with GSK — as CEO Anne Wojcicki calls it —has pushed one drug into the clinic in more than three years.

Yahoo | January 18, 2022

Unilever's GSK asset bid risks rating downgrade, says Fitch

Ratings agency Fitch said that Unilever's bid for GlaxoSmithKline's consumer health assets would put the consumer goods group's 'A' credit rating at risk because of the huge debt it would have to swallow. Unilever's 50 billion pound ($67.88 billion) initial bid for GSK's consumer health arm, which owns brands including Panadol painkillers and Sensodyne toothpaste, was rejected by the pharmaceuticals company. "Unilever's offer... is likely to raise Unilever's debt to an extent that it would not be able to reduce to levels consistent with an 'A' rating category over 2024-2025, opening the possibility of a multi-notch downgrade into the BBB category," Fitch said in a report https://www.fitchratings.com/research/corporate-finance/unilever-risks-downgrade-with-new-growth-strategy-18-01-2022.

Yahoo | January 18, 2022

Norway Savings Bank Buys FedEx Corp, Vanguard Dividend Appreciation FTF, ConocoPhillips, Sells ...

Investment company Norway Savings Bank (Current Portfolio) buys FedEx Corp, Vanguard Dividend Appreciation FTF, ConocoPhillips, SPDR Bloomberg Convertible Securities ETF, Visa Inc, sells Novartis AG, PIMCO Enhanced Short Maturity Active Exchange-Trad, iShares iBonds Dec 2021 Term Corporate ETF, Fortive Corp, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Norway Savings Bank.

Yahoo | January 18, 2022

Read More 'GSK' Stories Here

GSK Price Returns

1-mo 3.06%
3-mo 14.77%
6-mo 18.41%
1-year 24.24%
3-year 34.45%
5-year 49.97%
YTD 2.27%
2021 26.64%
2020 -17.79%
2019 29.12%
2018 13.70%
2017 -3.03%

GSK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GSK Dividend History

Continue Researching GSK

Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:

Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9253 seconds.